<DOC>
	<DOCNO>NCT00750386</DOCNO>
	<brief_summary>This trial determine feasibility toxicity dose intense ( every 2 week ) paclitaxel+carboplatin combination follow cytoreductive surgery patient stage Ic-IV ovarian cancer .</brief_summary>
	<brief_title>Paclitaxel Carboplatin Combination 1st Line Treatment Ovarian Carcinomas</brief_title>
	<detailed_description>Dose dense chemotherapy proven beneficial various oncological setting . It propose concept test ovarian cancer , support growth factor . It hypothesize , feasible , dose-dense chemotherapy may effective .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm ovarian cancer require standard chemotherapy Patients chemotherapy naive Patients may undergo cytoreductive surgery , may omit due dissemination Age &gt; 18 year . Performance status ( WHO ) 02 Life expectancy least three month . Adequate bone marrow function ( Absolute neutrophil count &gt; 1000/mm^3 , Platelet count &gt; 100000/mm^3 , Hemoglobin &gt; 9gr/mm^3 ) . Adequate liver ( Bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2mg/dl ) Informed consent Pregnant nursing Psychiatric illness social situation would preclude study compliance ' Other concurrent uncontrolled illness No invasive malignancy within past 5 year except nonmelanoma skin cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Dose-dense chemotherapy</keyword>
</DOC>